News Summaries

AI Race Heats Up: China Slashes Prices, US Giants Eye IPOs, Regulators Draw Red Lines

May was a whirlwind month for artificial intelligence. Chinese firms led the charge on affordability: DeepSeek cut its V4 Pro API price by 75%, charging just 0.025 yuan per million tokens, while Baidu’s new "Wenxin 5.1" model boasts training costs only about 6 % of comparable systems and topped the global "Arena" benchmark at rank 4. Both moves showcase China’s push for high‑cost‑performance and full‑stack deployment on domestic chips. Across the Pacific, U.S. AI powerhouses prepared for blockbuster stock market debuts. Elon Musk announced that his xAI venture will merge into SpaceX AI, and filings show SpaceX aims to raise $75‑80 billion in a Nasdaq listing that could value the company at $1.75 trillion. OpenAI and Anthropic are also racing toward IPOs, a trend that analysts say could reshape the broader market. At the same time, safety and regulation took center stage. The EU Parliament agreed to ban AI‑generated deep‑fake porn, while China’s ministries issued new guidelines demanding safe, controllable agent development. Britain’s *Nature* warned that chatbots can dispense dangerous advice, underscoring the need for stronger oversight. Finally, OpenAI rolled out GPT‑5.5 Instant, cutting hallucinations in high‑risk fields by more than half and boosting math and visual reasoning. The month ended with the U.S. Department of Defense signing agreements to embed cutting‑edge AI from SpaceX, OpenAI, Google and NVIDIA into classified combat networks, signaling an "AI‑first" future for the military.

Hong Kong Unveils Its First AI Super‑Agent to Boost Workplace Productivity

Hong Kong’s Generative AI Research and Development Center (HKGAI) announced a major milestone on June 3, unveiling the newest version of its home‑grown large‑language model, HKGAI V3, and launching the city’s first “productivity‑grade” AI super‑agent. Funded by the SAR government’s InnoHK innovation platform, the super‑agent is designed to work continuously for up to 28 hours without human help, handling a chain of tasks such as sorting data, performing reasoning, drafting reports and even writing code. The breakthrough aims to turn AI from a novelty into a practical tool for Hong Kong businesses, with the model trained on local data to better understand the city’s language, culture and market needs. Sun Dong, the SAR’s Secretary for Innovation, Technology and Industry, said the launch is part of a broader push to “industrialise AI and AI‑industrialise” the region, strengthening the local AI ecosystem. HKUST’s Guo Yike, who leads HKGAI, highlighted that V3 will support multi‑step workflows and deliver more efficient, intelligent solutions tailored to Hong Kong’s industries. A round‑table discussion at the event explored how local large models can empower sectors ranging from finance to manufacturing, emphasizing collaboration between government, academia and industry to build a vibrant AI future for the city.

Why Ozempic Fails for Some: The Genetic Roadblock Behind Weight‑Loss Resistance

A new study from Stanford Medicine explains why the popular weight‑loss drug Ozempic (a GLP‑1 receptor agonist) doesn’t work for everyone. Researchers discovered that a small genetic variation in the PAM gene can make the body less responsive to GLP‑1 signals, a condition they call “GLP‑1 resistance.” In people who carry this variant, the drug’s ability to curb appetite and promote weight loss is blunted, even though it still helps control blood sugar. The team traced the first hints of GLP‑1 resistance back almost ten years, long before GLP‑1 drugs became household names for slimming. They compared several clinical trials, noting that two longer‑acting GLP‑1 drugs seemed to overcome the resistance better than shorter‑acting versions. However, only a handful of trials reported weight‑loss data, and those results showed no clear difference between carriers and non‑carriers, leaving some questions unanswered. Funding for the research came from a mix of public and private sources, including the Wellcome Trust, the European Union, the NIH, and pharmaceutical companies like Novo Nordisk and Boehringer Ingelheim. The findings point toward a future where doctors could test for the PAM variant before prescribing Ozempic, tailoring obesity treatment to each patient’s genetic makeup and improving success rates.

China’s ‘Artificial Sun’ Moves Closer to Powering the Future – Fusion Milestones, New Reactor Plans, and Industry Boom

China is fast becoming a world leader in nuclear‑fusion research, the quest for a clean, virtually limitless energy source. In October 2025 the International Atomic Energy Agency opened its first global fusion‑energy research and training centre in Chengdu, underscoring China’s growing influence. The nation’s flagship machine, China Helios Three, has entered an upgrade phase and is slated to run its first domestic fusion‑combustion experiments in 2027, a crucial step from pure science to engineering proof‑of‑concept. Officials say a pilot fusion reactor is targeted for 2035, with a demonstration plant around 2045. This timeline is backed by new policies: the Atomic Energy Law (effective Jan 2026) legally encourages controlled thermonuclear research, while the State Council’s “Carbon‑Peak Action Plan” and the 15th Five‑Year Plan earmark fusion as a key growth engine and set technology milestones such as tritium‑fuel cycles, superconducting magnets and high‑performance lasers. China now sits alongside the United States, Europe and Japan in the top tier of fusion capability, boasting breakthroughs in long‑pulse control, neutral‑beam heating and reactor component design. A state‑run firm, China Fusion Energy Co., and a wave of private startups are accelerating commercialization, while spin‑off technologies are already lowering costs for green hydrogen production and improving semiconductor packaging. The next five years promise rapid innovation, a blossoming industry ecosystem, and, if all goes well, the first steps toward a real‑world “artificial sun.”

The Thymus: The Overlooked Organ That May Forecast Your Lifespan

A new study from Mass General Brigham shines a spotlight on the thymus, an immune organ that most adults have forgotten about. Researchers found that the size and health of the thymus can be a powerful, hidden indicator of how long a person might live, their risk for chronic diseases, and even how well they will respond to cancer therapies. While the thymus is well known for its role in training immune cells during childhood, it continues to influence the immune system throughout adulthood. The team discovered that people with a more robust thymus tend to have lower rates of heart disease, better metabolic health, and a stronger response to immunotherapies for cancer. Conversely, a shrunken or damaged thymus was linked to higher mortality and poorer treatment outcomes. These findings suggest that simple imaging or blood tests that assess thymus function could become routine tools for doctors to gauge overall health and personalize treatment plans. The research opens the door to potential therapies aimed at rejuvenating the thymus, offering a novel way to boost longevity and improve disease resistance in the aging population.

China Rolls Out Nationwide 6G Pilot to Fast‑Track Commercial Rollout by 2029

Beijing – On June 4, the Ministry of Industry and Information Technology announced a new “Ministry‑Province Coordination Pilot” aimed at turning 6G research into real‑world products by 2029. The program will spur local governments and companies to develop home‑grown 6G solutions, nurture fresh business scenarios and launch a wave of next‑generation devices. Key measures focus on four collaboration pillars: 1. **Technology research** – joint work on AI‑integrated communications, satellite internet, wireless sensing and other cutting‑edge fields to shape future standards. 2. **Industry R&D** – building regional 6G clusters that cover base stations, chips, terminals and operating‑system platforms. 3. **Application cultivation** – piloting use cases such as immersive video, smart manufacturing, low‑altitude logistics, embodied intelligence and “smart ocean” monitoring, backed by policy support, spectrum allocation and funding. 4. **Project layout** – aligning pilot projects across provinces to create a unified national innovation ecosystem. Experts say the initiative leverages China’s “national system” advantage, turning local strengths into a coordinated “one‑chess‑game” strategy. International bodies expect 6G specifications by 2030, and the China Academy of Information and Communications projects a trillion‑yuan market by 2035. The pilot is seen as a decisive step toward making 6G a commercial reality.

Chinese Researchers Give Robots a ‘Thinking Brain’ – Wins Global Competition

At the 2026 International Conference on Robotics and Automation (ICRA) in Vienna, a team from the Institute of Automation, Chinese Academy of Sciences, stunned the world by showing robots that can think before they act. Their creation, called NeoVerse‑ABot, topped the Embodied Intelligence Challenge’s world‑model track, beating 525 other teams from 27 countries with a record‑high score of 0.829. What makes NeoVerse‑ABot special? Instead of merely reacting to visual input, the system builds an internal “simulation” of the scene, predicts how objects will move, and decides the safest way to grasp or manipulate them. This lets the robot anticipate problems like a slipping cup or a missed grab, something traditional robots can’t do. The researchers tackled a notorious issue known as “action hallucination,” where AI imagines perfect outcomes that ignore physics. By feeding the model massive amounts of real‑world failure data—empty grasps, slips, mis‑alignments—and rewarding true physical consistency through reinforcement learning, NeoVerse‑ABot learned to distinguish success from failure. The breakthrough is more than academic; it aligns with China’s 15‑Year Plan to make embodied intelligence a flagship industry. With a “thinking brain,” robots could soon move from labs into factories, homes, and hospitals, performing tasks safely and reliably alongside humans.